File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An international research agenda for clozapine-resistant schizophrenia

TitleAn international research agenda for clozapine-resistant schizophrenia
Authors
Issue Date14-Jun-2023
PublisherElsevier
Citation
The Lancet Psychiatry, 2023, v. 10, n. 8, p. 644-652 How to Cite?
AbstractTreatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.
Persistent Identifierhttp://hdl.handle.net/10722/341619
ISSN
2023 SCImago Journal Rankings: 7.827
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLuykx, JJ-
dc.contributor.authorGonzalez-Diaz, JM-
dc.contributor.authorGuu, TW-
dc.contributor.authorVan der Horst, MZ-
dc.contributor.authorVan Dellen, E-
dc.contributor.authorBoks, MP-
dc.contributor.authorGuloksuz, S-
dc.contributor.authorDeLisi, LE-
dc.contributor.authorSommer, IE-
dc.contributor.authorCummins, R-
dc.contributor.authorShiers, D-
dc.contributor.authorLee, J-
dc.contributor.authorEvery-Palmer, S-
dc.contributor.authorMhalla, A-
dc.contributor.authorChadly, Z-
dc.contributor.authorChan, SKW-
dc.contributor.authorCotes, RO-
dc.contributor.authorTakahashi, S-
dc.contributor.authorBenros, ME-
dc.contributor.authorWagner, E-
dc.contributor.authorCorrell, CU-
dc.contributor.authorHasan, A-
dc.contributor.authorSiskind, D-
dc.contributor.authorEndres, D-
dc.contributor.authorMacCabe, J-
dc.contributor.authorTiihonen, J-
dc.date.accessioned2024-03-20T06:57:48Z-
dc.date.available2024-03-20T06:57:48Z-
dc.date.issued2023-06-14-
dc.identifier.citationThe Lancet Psychiatry, 2023, v. 10, n. 8, p. 644-652-
dc.identifier.issn2215-0366-
dc.identifier.urihttp://hdl.handle.net/10722/341619-
dc.description.abstractTreatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofThe Lancet Psychiatry-
dc.titleAn international research agenda for clozapine-resistant schizophrenia-
dc.typeArticle-
dc.identifier.doi10.1016/S2215-0366(23)00109-8-
dc.identifier.pmid37329895-
dc.identifier.scopuseid_2-s2.0-85165341293-
dc.identifier.volume10-
dc.identifier.issue8-
dc.identifier.spage644-
dc.identifier.epage652-
dc.identifier.eissn2215-0374-
dc.identifier.isiWOS:001163329200001-
dc.identifier.issnl2215-0366-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats